Rojda Tanrıverdi

Rojda Tanrıverdi

Auto-generated profile, based on publicly available information

Rojda Tanrıverdi

Department of Biochemistry, Mersin University Faculty of Medicine Hospital, 33110 Mersin, Turkey

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2024 in BMC Urology
Verified
Journal Article
Open access
PDF file
ANAli Nebioğlu
Ali Nebioğlu
RTRojda Tanrıverdi
Rojda Tanrıverdi
MBMert Başaranoğlu
Mert Başaranoğlu
BSBarış Saylam
Barış Saylam
EUErcüment Ulusoy
Ercüment Ulusoy
SESemra Erdoğan
Semra Erdoğan
Bladder cancer continues to be a significant health issue, leading to ongoing research into novel biomarkers and treatment strategies. This study aims to evaluate the potential of serum fibronectin levels and fibronectin gene polymorphisms as biomarkers for predicting the recurrence and treatment response in patients with NMIBC undergoing intravesical BCG therapy. Between June 2022 and December 2022, data of 73 patients who applied to the Mersin University Urology Clinic due to NMIBC and were followed and treated in our clinic, receiving intravesical BCG treatment, when necessary, as well as 56 individuals without any malignancy, were prospectively examined. Serum fibronectin levels were measured using the enzyme-linked immunosorbent assay method. PCR testing was applied for the fibronectin gene RS10202709 and RS 35,343,655 gene polymorphisms by using Real-Time PCR. The mean serum fibronectin level in the patient group was 76.794 ± 66.998ng/ml. Simultaneously, it was 50.486 ± 25.156ng/ml in the control group, and these differences in serum fibronectin levels were statistically significant(p = 0.003). Out of the 73 patients included in the study, recurrence of bladder cancer was observed in 53 of them. They were divided into two groups based on the recurrence times: early recurrence and late recurrence. The mean fibronectin level in the early recurrence group was 102 ± 86.1 ng/ml, while it was 44.7 ± 11.8 ng/ml in the late recurrence group. Emphasize the significance of the higher fibronectin levels in the early recurrence group by stating, patients with early recurrence exhibited significantly higher serum fibronectin levels compared to those with late recurrence (p < 0.001), suggesting a potential role for fibronectin as a prognostic biomarker. The statistically higher concentrations of serum fibronectin levels in patients with bladder cancer observed in our study are a noteworthy finding. These findings suggest that serum fibronectin levels could serve as a valuable prognostic biomarker for early recurrence in NMIBC patients, although their predictive value for BCG treatment response remains limited.

8 August 2024 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
MBMelih Bıyıkoğlu
Melih Bıyıkoğlu
RTRojda Tanrıverdi
Rojda Tanrıverdi
MBMurat Bozlu
Murat Bozlu
SSSamet Senel
Samet Senel
ŞFŞenay Balcı Fidancı
Şenay Balcı Fidancı
EAErdem Akbay
Erdem Akbay

31 July 2025 in Dermatology Practical & Conceptual
Verified
Journal Article
Open access
PDF file
MÇMelodi Çekiç
Melodi Çekiç
AKAyşın köktürk
Ayşın köktürk
LTLülüfer Tamer
Lülüfer Tamer
RTRojda Tanrıverdi
Rojda Tanrıverdi
Introduction: Rosacea, a chronic skin disease characterized by facial redness, is believed to involve inflammation and angiogenesis in its pathogenesis. Endocan and endoglin, biomarkers associated with vascular and inflammatory processes, might play roles in rosacea and cardiovascular comorbidities. Objectives: This study aims to assess serum levels of endocan and endoglin in individuals with rosacea and the function of these biomarkers in indicating comorbidities associated with rosacea. Methods: A total of 44 patients diagnosed with rosacea and 34 healthy controls were included in this case-control study. The endocan and endoglin levels in serum samples from both groups were measured. Results: No significant differences in endocan and endoglin levels were observed between the patient and control groups. However, their levels were associated with various clinical features, including symptom and disease severity. A notable association was identified between waist circumference, body mass index and endoglin levels. However, this association was not evident for endocan. Conclusions: This study suggests endocan and endoglin may play roles in rosacea pathogenesis, with endoglin potentially associated with increased cardiovascular risk.

Verified
Journal Article
Open access
PDF file
RBRIDVAN BORA
RIDVAN BORA
BTBurak Toprak
Burak Toprak
EYEmrah Yeşil
Emrah Yeşil
RTRojda Tanrıverdi
Rojda Tanrıverdi
MAMuhammed Adıyaman
Muhammed Adıyaman
ODOben Döven
Oben Döven
Background: Inflammation plays a central role in the pathophysiology of acute coronary syndrome (ACS). Raftlin, a lipid raft-associated inflammatory protein involved in immune signaling, has emerged as a potential biomarker in cardiovascular disease. This study aimed to evaluate circulating raftlin levels and RFTN1 rs690037 polymorphism in patients with ACS. Methods: This prospective observational study included 100 participants comprising 50 patients diagnosed with ACS and 50 control subjects with angiographically normal coronary arteries. Serum raftlin concentrations were measured using enzyme-linked immunosorbent assay, and RFTN1 rs690037 polymorphisms were analyzed by real-time polymerase chain reaction. Correlation, receiver operating characteristic (ROC), multivariable logistic regression, and net reclassification improvement (NRI) analyses were performed. Results: Serum raftlin levels were significantly higher in the ACS group compared with controls (4.28 [3.48–5.78] vs. 3.38 [2.66–4.23] ng/dL, p = 0.003). Raftlin levels demonstrated significant positive correlations with LDL cholesterol and HbA1c levels in ACS patients (p < 0.05 for both). ROC analysis showed that raftlin had moderate discriminative ability for ACS detection (AUC: 0.672, 95% CI: 0.570–0.762, p = 0.002). Although raftlin was not independently associated with ACS after multivariable adjustment, incorporation of raftlin into the baseline clinical model improved overall risk classification (NRI: 0.213, p = 0.041). No significant association was observed between RFTN1 rs690037 polymorphism and ACS or circulating raftlin levels. Conclusions: Circulating raftlin levels are elevated in patients with ACS and appear to reflect the inflammatory and metabolic dysregulation accompanying acute coronary events. Although raftlin alone demonstrated limited diagnostic performance, its incremental contribution to multimarker risk assessment models suggests potential utility as a complementary inflammatory biomarker in ACS. Larger multicenter studies are warranted to clarify its prognostic and translational significance.

Verified
Journal Article
Open access
PDF file
RBRIDVAN BORA
RIDVAN BORA
RTRojda Tanrıverdi
Rojda Tanrıverdi
ŞFŞenay Balcı Fidancı
Şenay Balcı Fidancı
BTBurak Toprak
Burak Toprak
CGCemil Gülüm
Cemil Gülüm
LTLülüfer Tamer
Lülüfer Tamer
Background/Objectives: Coronary artery disease is a chronic inflammatory disorder characterized by progressive atherosclerosis and heterogeneous clinical presentations ranging from acute coronary events to stable ischemic conditions. Galectin-3 is a β-galactoside-binding lectin involved in inflammatory responses, fibrosis, and tissue remodeling, and has been investigated as a potential biomarker in cardiovascular diseases. However, its diagnostic significance across different clinical stages of coronary artery disease remains unclear. Methods: This prospective study included 180 participants who underwent coronary angiography and were classified into three groups: control (n = 60), acute coronary syndrome (n = 60), and chronic coronary syndrome (n = 60). Serum Galectin-3 concentrations were measured using an enzyme-linked immunosorbent assay. Group comparisons were performed using non-parametric statistical tests. Correlation analysis, receiver operating characteristic curve analysis, and multivariable logistic regression were conducted to evaluate diagnostic performance and independent associations. Results: Galectin-3 concentrations were significantly higher in both acute coronary syndrome and chronic coronary syndrome groups compared with the control group (p < 0.001), whereas no significant difference was observed between the two disease groups. Receiver operating characteristic analysis demonstrated limited diagnostic performance for identifying acute coronary syndrome (area under the curve 0.617, sensitivity 96.7%, specificity 43.3%, p = 0.027) and poor diagnostic performance for chronic coronary syndrome (area under the curve 0.541, sensitivity 91.7%, specificity 30.0%, p = 0.436). In multivariable analysis, Galectin-3 was not identified as an independent predictor of either clinical condition. Age and smoking were independently associated with acute coronary syndrome, while age and male sex were independently associated with chronic coronary syndrome. Conclusions: Galectin-3 levels are elevated in patients with coronary artery disease and appear to reflect the inflammatory burden associated with atherosclerosis. However, its diagnostic discrimination between different clinical stages of coronary artery disease remains limited. Larger prospective studies are required to clarify its clinical value.

18 December 2022 in Ahi Evran Medical Journal
Verified
Journal Article
Open access
RTRojda Tanriverdi̇
Rojda Tanriverdi̇
Aim: Atherosclerosis is defined as an inflammatory disease that results in the formation of atherosclerotic plaques caused by the deposition of cholesterol in the arterial intima. As a result of damage to the intima layer of the vessel, foam cell formation following cholesterol accumulation and plaque development due to smooth muscle cell increase are observed. In different stages of atherosclerosis, migration of leukocytes to the vessel wall is provided by functional type chemokines; It was aimed to investigate the possible role of MIF -173G/C polymorphism in atherosclerosis disease depending on this function, since it has the same functional properties as chemokines. Material and Method: Thirty patients with 70% occlusion detected by angiography and 30 healthy individuals were included in the study. DNA isolation was performed from blood samples taken from individuals in EDTA tubes. Analysis of MIF -173G/C polymorphism was performed on Real Time PCR (LC480, Roche). Statistical analyzes were performed using the STATISTICA version 13.5.0.17 (TIBCO Software Inc. (2017)) program. Results: In the MIF -173G/C polymorphism, the frequency of GG, GC and CC genotypes in the patient group was 55.26%, 41.18% and 66.66%, and 44.74%, 58.82% and 33.33% in the control group, respectively. Compared with the GG genotype, it was determined that those with the GC genotype had a 0.567-fold (p=0.3367) risk of developing the disease, and those with the CC genotype had a 1.6190-fold (p= 0.7038) risk of developing the disease. Conclusion: Further studies can be carried out by increasing the number of samples.